Article type: Editorial

Home Page URL: https://www.alliedacademies.org/virology-research/

Can personalized medicine defeat drug resistance?

Gary Washington*

Division of Infectious Diseases, Brigham and Women's Hospital, USA

***Correspondence to:** Gary Washington, Division of Infectious Diseases, Harvard Medical School, USA, E-mail: Gary.w@ga.us

***Received:** 04-Jul-2024, Manuscript No. AAVRJ-25-169235; **Editor assigned:** 05-Jul-2024, PreQC No. AAVRJ-23-169235(PQ); **Reviewed:** 19-Jul-2024, QC No. AAVRJ -23-11210; **Revised:** 23-Jul-2024, Manuscript No. AAVRJ -23-169235(R); **Published:** 30-Jul-2024, DOI:10.35841/aavrj-8.2.178*

Introduction

Drug resistance is one of the most formidable challenges in modern medicine. From cancer to infectious diseases, the ability of pathogens and abnormal cells to evade therapeutic interventions has led to treatment failures, increased mortality, and soaring healthcare costs. As traditional "one-size-fits-all" approaches falter, personalized medicine—tailoring treatment based on individual genetic, molecular, and environmental profiles—has emerged as a promising strategy to outmaneuver resistance mechanisms. But can it truly defeat drug resistance?Drug resistance occurs when diseases no longer respond to medications that were once effective. This phenomenon is driven by: Genetic mutations in pathogens or cancer cells Epigenetic changes that alter gene expression Drug efflux mechanisms that pump drugs out of cells [1, 2].

Altered drug targets that reduce binding efficacy Tumor heterogeneity, where different cell populations respond differently. In cancer, for example, resistance can be intrinsic (present before treatment) or acquired (develops during therapy). Similarly, bacteria evolve resistance through horizontal gene transfer and selective pressure from antibiotic overuse. Personalized medicine, also known as precision medicine, leverages genomic, proteomic, and metabolomic data to customize treatment. Its core principles include: Targeted therapies based on molecular profiling. Pharmacogenomics to predict drug response and toxicity [3, 4].

Biomarker-driven decisions for early detection and monitoring. Adaptive treatment strategies that evolve with disease progression. This approach shifts the paradigm from reactive to proactive care, aiming to prevent resistance before it emerges. Cancer treatment has seen the most dramatic impact of personalized medicine: Pharmacogenetic testing identifies mutations like EGFR, ALK, and BRAF to guide targeted therapies. Liquid biopsies detect circulating tumor DNA, allowing real-time monitoring of resistance mutations. Dynamic Precision Medicine (DPM) uses mathematical models to design individualized treatment sequences that anticipate resistance [5, 6].

For instance, patients with non-small cell lung cancer harboring EGFR mutations respond well to tyrosine kinase inhibitors—until resistance mutations like T790M emerge. Personalized medicine enables switching to third-generation inhibitors like osimertinib. AMR is a global crisis, with predictions of 10 million deaths annually by 2050 if unchecked. Personalized medicine offers solutions: Rapid molecular diagnostics identify resistant strains and guide antibiotic selection. Host-pathogen interaction profiling tailors immunomodulatory therapies. Precision antimicrobial dosing minimizes subtherapeutic exposure that fosters resistance [7, 8].

For example, tuberculosis treatment now incorporates genetic testing for rifampicin resistance, enabling tailored regimens that improve outcomes and reduce transmission. Artificial intelligence enhances personalized medicine by: Predicting resistance patterns from genomic data Optimizing drug combinations using reinforcement learning Integrating multi-omics data for holistic treatment planning Despite its promise, personalized medicine faces hurdles: High costs of genomic testing and targeted drugs Limited access in low-resource settings, Ethical concerns around genetic privacy and discrimination, Incomplete understanding of resistance mechanisms in complex diseases. Moreover, resistance can still emerge even with personalized approaches, especially when tumors evolve new escape

pathways or when pathogens acquire novel resistance genes [9, 10].

Conclusion

Personalized medicine is not a silver bullet—but it is a powerful weapon in the fight against drug resistance. By tailoring therapies to individual biology and anticipating resistance mechanisms, it offers a path toward more effective, durable, and humane treatments. The journey is complex, but the destination—a world where resistance no longer dictates outcomes—is worth striving for.

References

1. Chen J. Activation of latent Kaposi's sarcoma-associated herpesvirus by demethylation of the promoter of the lytic transactivator. Proc Natl Acad Sci U S A. 2001;98(7):4119-24.
2. Chang PC. Histone demethylase JMJD2A regulates Kaposi's sarcoma-associated herpesvirus replication and is targeted by a viral transcriptional factor. J Virol. 2011;85(7):3283-93.
3. Toth Z, Brulois K, Jung JU. The chromatin landscape of Kaposi's sarcoma-associated herpesvirus. Viruses. 2013;5:1346–1373.
4. Queen KJ Cve U, Scott RS. Epstein-Barr virus-induced epigenetic alterations following transient infection. Int J Cancer. 2013;132(9):2076-86.
5. Caliskan M, Ober C. The effects of EBV transformation on gene expression levels and methylation profiles. Hum Mol Genet. 2011;20(8):1643-52.

Citation: Washington G. Can personalized medicine defeat drug resistance. Virol Res J. 2024;8(2):178